Aileen Rubio, PhD, is the Head of Biology for Spero Therapeutics in Cambridge, MA. She previously held positions of increasing responsibility at Cubist Pharmaceuticals, where she worked for over 9 years. During that time, she worked on antibacterial discovery projects, as well as provided support for business development activities. She has also collaborated with several key opinion leaders to investigate the mechanism of action/resistance of Cubicin (daptomycin for injection) in Staphylococcus aureus.
Dr. Rubio received BS degrees in both Microbiology and Chemistry from the University of Illinois at Champaign-Urbana, a PhD in Bacteriology from the University of Wisconsin at Madison and completed post-doctoral research at the University of California at San Diego.